

# Paul B Chapman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7955681/publications.pdf>

Version: 2024-02-01

98  
papers

28,608  
citations

50244

46  
h-index

42364

92  
g-index

100  
all docs

100  
docs citations

100  
times ranked

26587  
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. <i>New England Journal of Medicine</i> , 2011, 364, 2507-2516.	13.9	6,976
2	Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2010, 363, 809-819.	13.9	3,288
3	Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. <i>Lancet</i> , The, 2012, 380, 358-365.	6.3	2,691
4	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. <i>Nature</i> , 2010, 467, 596-599.	13.7	1,610
5	Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. <i>Nature</i> , 2012, 487, 500-504.	13.7	1,561
6	RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). <i>Nature</i> , 2011, 480, 387-390.	13.7	1,298
7	<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors. <i>New England Journal of Medicine</i> , 2012, 366, 207-215.	13.9	978
8	Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. <i>Journal of Clinical Oncology</i> , 2015, 33, 3193-3198.	0.8	892
9	Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology</i> , The, 2014, 15, 323-332.	5.1	890
10	Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 1087-1095.	5.1	841
11	Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 2745-2745.	0.8	716
12	Evolutionary dynamics of cancer in response to targeted combination therapy. <i>ELife</i> , 2013, 2, e00747.	2.8	516
13	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. <i>Lancet Oncology</i> , The, 2018, 19, 310-322.	5.1	486
14	The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 14903-14908.	3.3	417
15	Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2397.	3.8	359
16	<i>PTEN</i> Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2017, 1, 1-15.	1.5	275
17	Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence. <i>Cancer Research</i> , 2014, 74, 2340-2350.	0.4	266
18	Cross-presentation of Disialoganglioside GD3 to Natural Killer T Cells. <i>Journal of Experimental Medicine</i> , 2003, 198, 173-181.	4.2	257

#	ARTICLE	IF	CITATIONS
19	Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysis. <i>Cancer</i> , 1993, 72, 3091-3098.	2.0	222
20	Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment. <i>New England Journal of Medicine</i> , 2012, 367, 2316-2321.	13.9	222
21	Phase III Study of Adjuvant Vaccination With Bac2/Bacille Calmette-Guerin in Responding Patients With Limited-Disease Small-Cell Lung Cancer (European Organisation for Research and Treatment of Cancer) Tj ETQq1 1 0.784314mgBT /Oy	0.7	142
22	Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). <i>Journal of Clinical Oncology</i> , 2018, 36, 1232-1239.	0.8	207
23	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 510-520.	5.1	183
24	Marked, Homogeneous, and Early [ <sup>18</sup> F]Fluorodeoxyglucoseâ€“Positron Emission Tomography Responses to Vemurafenib in <i>BRAF</i> -Mutant Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1628-1634.	0.8	172
25	Phase II Study of Temozolomide Plus Thalidomide for the Treatment of Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 3351-3356.	0.8	146
26	Ipilimumab for Patients With Advanced Mucosal Melanoma. <i>Oncologist</i> , 2013, 18, 726-732.	1.9	140
27	Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade. <i>Journal of Clinical Oncology</i> , 2020, 38, 1655-1663.	0.8	138
28	Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma. <i>Clinical Cancer Research</i> , 2013, 19, 2257-2264.	3.2	136
29	Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. <i>Clinical Cancer Research</i> , 2015, 21, 2289-2296.	3.2	128
30	Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. <i>JAMA Oncology</i> , 2018, 4, 98.	3.4	125
31	Evaluation of CD8+ T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. <i>International Journal of Cancer</i> , 2000, 87, 391-398.	2.3	98
32	Opportunistic infections in patients treated with immunotherapy for cancer. , 2014, 2, 19.		98
33	Clinical and Morphologic Characteristics of MEK Inhibitorâ€“Associated Retinopathy. <i>Ophthalmology</i> , 2017, 124, 1788-1798.	2.5	95
34	Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation. <i>Nature Communications</i> , 2015, 6, 6840.	5.8	87
35	Vemurafenib Sensitivity Skin Reaction after Ipilimumab. <i>New England Journal of Medicine</i> , 2012, 366, 866-868.	13.9	82
36	Title is missing!. , 2017, , .		82

#	ARTICLE	IF	CITATIONS
37	Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies. <i>Cancer Discovery</i> , 2014, 4, 538-545.	7.7	73
38	Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. <i>Cancer Cell</i> , 2018, 34, 852-862.e4.	7.7	73
39	Phase II Study of Extended-Dose Temozolomide in Patients With Melanoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 2299-2304.	0.8	66
40	The History and Future of Chemotherapy for Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 583-597.	0.9	66
41	Sequential Immunization of Melanoma Patients with GD3 Ganglioside Vaccine and Anti-Idiotypic Monoclonal Antibody That Mimics GD3 Ganglioside. <i>Clinical Cancer Research</i> , 2004, 10, 4717-4723.	3.2	62
42	Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. <i>European Journal of Cancer</i> , 2015, 51, 1435-1443.	1.3	61
43	Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. <i>Oncotarget</i> , 2016, 7, 85430-85436.	0.8	60
44	Clinical significance of BRAF mutations in metastatic melanoma. <i>Journal of Translational Medicine</i> , 2004, 2, 46.	1.8	58
45	Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy. <i>New England Journal of Medicine</i> , 2015, 372, 2073-2074.	13.9	57
46	A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. <i>Oncologist</i> , 2015, 20, 789-797.	1.9	57
47	Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw260.	3.0	56
48	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	54
49	Combination of RAF and MEK Inhibition for the Treatment of BRAF-Mutated Melanoma: Feedback Is Not Encouraged. <i>Cancer Cell</i> , 2014, 26, 603-604.	7.7	49
50	Phase II study of temozolomide plus pegylated interferon- $\gamma$ -2b for metastatic melanoma. <i>Cancer</i> , 2006, 106, 2445-2451.	2.0	44
51	A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States. <i>Cancer Journal (Sudbury, Mass )</i> , 2014, 20, 18-24.	1.0	43
52	A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma. <i>Cancer</i> , 1995, 75, 2251-2257.	2.0	42
53	Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2017, 24, 939-946.	0.7	41
54	Detection of Mutant BRAF Alleles in the Plasma of Patients with Metastatic Melanoma. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 178-183.	1.2	40

#	ARTICLE	IF	CITATIONS
55	Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. <i>Annals of Surgical Oncology</i> , 2020, 27, 1180-1188.	0.7	39
56	Osteonecrosis of the jaw a new complication related to Ipilimumab. <i>Oral Oncology</i> , 2015, 51, e100-e101.	0.8	38
57	MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 328-338.	1.5	34
58	Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 3239-3246.	3.2	32
59	Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. , 2013, 1, 20.		31
60	Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience. <i>Oncologist</i> , 2019, 24, e196-e197.	1.9	31
61	Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF V600E-mutated melanoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA8500-LBA8500.	0.8	31
62	Immune Checkpoint Inhibitor-Associated Optic Neuritis. <i>Ophthalmology</i> , 2020, 127, 1585-1589.	2.5	30
63	A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. <i>Vaccine</i> , 2004, 22, 2904-2909.	1.7	29
64	The Role of Neoadjuvant Trials in Drug Development for Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 2323-2328.	3.2	28
65	Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study). <i>Journal of Clinical Oncology</i> , 2022, 40, 1059-1067.	0.8	26
66	A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma. <i>Cancer</i> , 1991, 68, 1230-1237.	2.0	25
67	Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1962-1971.	1.9	25
68	Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. <i>Clinical Cancer Research</i> , 2021, 27, 2226-2235.	3.2	25
69	Adjuvant Therapy of Melanoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2007, 13, 217-222.	1.0	24
70	Safety of Infusing Ipilimumab Over 30 Minutes. <i>Journal of Clinical Oncology</i> , 2015, 33, 3454-3458.	0.8	24
71	Melanoma Vaccines. <i>Seminars in Oncology</i> , 2007, 34, 516-523.	0.8	21
72	Time to publication of oncology trials and why some trials are never published. <i>PLoS ONE</i> , 2017, 12, e0184025.	1.1	19

#	ARTICLE	IF	CITATIONS
73	Helping Melanoma Patients Decide Whether to Choose Adjuvant High-Dose Interferon-2b. <i>Oncologist</i> , 2005, 10, 739-742.	1.9	17
74	Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. <i>Clinical Cancer Research</i> , 2015, 21, 5215-5221.	3.2	17
75	Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. , 2022, 10, e003853.		16
76	Immunotherapy of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 751-766.	0.9	15
77	Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). <i>Melanoma Research</i> , 2021, 31, 67-75.	0.6	15
78	Patient perspectives on ipilimumab across the melanoma treatment trajectory. <i>Supportive Care in Cancer</i> , 2017, 25, 2155-2167.	1.0	14
79	Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody. <i>Current Opinion in Investigational Drugs</i> , 2003, 4, 710-5.	2.3	13
80	Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF <sup>V600E</sup> -mutated melanoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA8500-LBA8500.	0.8	12
81	Discordance Between Cobas BRAF V600 Testing and VE1 Immunohistochemistry in a Melanoma Patient With Bone Marrow Metastases. <i>American Journal of Dermatopathology</i> , 2016, 38, 687-689.	0.3	11
82	Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation. <i>Oncotarget</i> , 2017, 8, 105000-105010.	0.8	10
83	Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab. , 2021, 9, e003395.		7
84	PD-1 or PD-L1 Blockade Adds Little to Combination of BRAF and MEK Inhibition in the Treatment of BRAF V600E-Mutated Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1393-1395.	0.8	7
85	Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker. <i>Clinical Cancer Research</i> , 2016, 22, 2114-2120.	3.2	6
86	A step forward for patients with NRAS-mutant melanoma. <i>Lancet Oncology</i> , The, 2017, 18, 414-415.	5.1	6
87	Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2005, 22, 749-760.	0.5	6
88	The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas. <i>Clinical Cancer Research</i> , 2021, 27, 1516-1525.	3.2	6
89	Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib. <i>Clinical Cancer Research</i> , 2016, 22, 1341-1347.	3.2	5
90	Targeting Tumor-Rejection Antigens in Melanoma With Tumor-Infiltrating Lymphocytes. <i>Journal of Clinical Oncology</i> , 2021, 39, 2640-2642.	0.8	5

#	ARTICLE	IF	CITATIONS
91	Counterpoint: The Case Against Adjuvant High-Dose Interferon- $\alpha$ for Melanoma Patients. Journal of the National Comprehensive Cancer Network: JNCCN, 2004, 2, 69-72.	2.3	4
92	Frontline Approach to Metastatic <i>BRAF</i> -Mutant Melanoma Diagnosis, Molecular Evaluation, and Treatment Choice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e412-e421.	1.8	4
93	Elevated Levels of <i>BRAF</i> <sup>V600</sup> Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma. JCO Precision Oncology, 2018, 2, 1-17.	1.5	3
94	Changing the standard of care for treating melanoma brain metastases. Lancet Oncology, The, 2018, 19, 589-591.	5.1	2
95	Treating Metastatic Melanoma in 2014: What Just Happened and What Is Next?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 16-19.	1.8	1
96	Targeted Inhibition of B-Raf. , 2012, , 63-76.		1
97	Immunotherapy of melanoma. Cancer Chemotherapy and Biological Response Modifiers, 2002, 20, 371-83.	0.5	1
98	Reply to A. Indini et al. Journal of Clinical Oncology, 2016, 34, 1018-1019.	0.8	0